Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. United States
  4. Nyse
  5. Pfizer, Inc.
  6. Financials
    PFE   US7170811035

PFIZER, INC.

(PFE)
  Report
Real-time Estimate Cboe BZX  -  08:38 2022-08-16 am EDT
49.69 USD   -0.12%
06:43aPfizer Inc. - Statement from Pfizer Chairman and CEO Albert Bourla on Testing Positive for COVID-19
AQ
04:44aDigital innovations and congress coverage led to an increase in all hub users
AQ
08/15Pfizer CEO tests positive for COVID-19, has mild symptoms
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Valuation
Fiscal Period: December 2019 2020 2021 2022 2023 2024
Capitalization1 216 827204 605331 440279 215--
Enterprise Value (EV)1 259 147232 220338 807267 693258 489240 184
P/E ratio 13,7x21,5x15,3x8,83x11,6x14,5x
Yield 3,68%4,13%2,64%3,26%3,36%3,44%
Capitalization / Revenue 4,19x4,88x4,08x2,75x3,61x4,14x
EV / Revenue 5,01x5,54x4,17x2,63x3,34x3,56x
EV / EBITDA 12,3x13,0x13,3x5,80x6,99x8,18x
Price to Book 3,43x3,24x4,30x2,82x2,51x2,38x
Nbr of stocks (in thousands) 5 534 1225 558 3975 612 8675 612 352--
Reference price (USD) 39,236,859,149,849,849,8
Announcement Date 01/28/202002/02/202102/08/2022---
1 USD in Million
Previous periodNext period
Estimates
Income Statement Evolution (Annual data)
Fiscal Period: December 2019 2020 2021 2022 2023 2024
Net sales1 51 75041 90881 288101 64877 40567 497
EBITDA1 21 09717 80125 42646 17336 97629 369
Operating profit (EBIT)1 19 42013 02420 23541 32829 71125 151
Operating Margin 37,5%31,1%24,9%40,7%38,4%37,3%
Pre-Tax Profit (EBT)1 17 6827 49724 31137 69426 13319 798
Net income1 16 2739 61621 97932 67522 87918 138
Net margin 31,4%22,9%27,0%32,1%29,6%26,9%
EPS2 2,871,713,855,644,293,42
Dividend per Share2 1,441,521,561,621,671,71
Announcement Date 01/28/202002/02/202102/08/2022---
1 USD in Million
2 USD
Previous periodNext period
Estimates
Income Statement Evolution (Quarterly data)
Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1
Net sales1 23 83825 66127 74221 96224 64121 053
EBITDA1 4 40311 135-11 7338 050-
Operating profit (EBIT)1 3 1269 94812 4089 3617 9698 348
Operating Margin 13,1%38,8%44,7%42,6%32,3%39,7%
Pre-Tax Profit (EBT) -9 050----
Net income1 3 3937 8649 9068 0206 639-
Net margin 14,2%30,6%35,7%36,5%26,9%-
EPS2 0,591,371,731,421,09-
Dividend per Share ------
Announcement Date 02/08/202205/03/202207/28/2022---
1 USD in Million
2 USD
Previous periodNext period
Estimates
Balance Sheet Analysis
Fiscal Period: December 2019 2020 2021 2022 2023 2024
Net Debt1 42 32027 6157 367---
Net Cash position1 ---11 52220 72639 030
Leverage (Debt / EBITDA) 2,01x1,55x0,29x-0,25x-0,56x-1,33x
Free Cash Flow1 10 41212 15129 86935 55527 53523 749
ROE (Net Profit / Equities) 25,7%15,2%31,3%41,3%25,6%17,9%
Shareholders' equity1 63 27563 18070 22079 18289 204101 162
ROA (Net Profit / Asset) 9,96%5,98%13,1%18,8%11,6%9,91%
Assets1 163 456160 910167 853174 044197 841183 050
Book Value Per Share2 11,411,413,717,719,820,9
Cash Flow per Share2 2,222,565,716,624,933,84
Capex1 2 1762 2522 7112 7952 7562 529
Capex / Sales 4,20%5,37%3,34%2,75%3,56%3,75%
Announcement Date 01/28/202002/02/202102/08/2022---
1 USD in Million
2 USD
Previous periodNext period
Estimates
Analysis
Biotech stocks pin bounce back hopes on M&A boost
Key data
Capitalization (USD) 279 214 502 497
Net sales (USD) 81 288 000 000
Number of employees 79 000
Sales / Employee (USD) 1 028 962
Free-Float 59,0%
Free-Float capitalization (USD) 164 613 799 703
Avg. Exchange 20 sessions (USD) 993 594 485
Average Daily Capital Traded 0,36%
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA